Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial Results
Neurocrine Biosciences (Nasdaq: NBIX) will report its fourth quarter and year-end 2020 financial results on February 4, 2021, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Neurocrine Biosciences (Nasdaq: NBIX) will report its fourth quarter and year-end 2020 financial results on February 4, 2021, after market close. A conference call and webcast will follow at 1:30 p.m. PT to discuss these results and provide a company update. Interested participants can join the call using the provided access numbers or through the company’s website. Neurocrine focuses on developing treatments for neurological and psychiatric disorders, boasting a portfolio that includes FDA-approved therapies.
Details
News Market Reaction – NBIX
The recorded move for NBIX in the trading session of this news was +3.53%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Jan. 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report fourth quarter and year-end 2020 financial results after the Nasdaq market closes on Thursday, Feb. 4, 2021. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
Participants can access the live conference call by dialing 800-895-3361 (US) or 785-424-1062 (International) using the conference ID: NBIX. The webcast can also be accessed on Neurocrine's website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)
View original content to download multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-fourth-quarter-and-year-end-2020-financial-results-301211835.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.